|

Blinatumomab and Inotuzumab Ozogamicin Clinical Trials

1 actively recruiting trial

Also known as: Full-Course Immunotherapy

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Soochow University1

Indications

  • Inotuzumab Ozogamicin1
  • Blinatumomab1
  • Immunotherapy1
  • Acute Lymphoblastic Leukemia1
  • Cancer1

Other1 trial

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.